Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2016-01-21367,2016,Guedes 2016 Medicine (Baltimore),33000,Primary Medical Treatment VERSUS Primary Surgical treatment IN Specific disease- Moderate glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.,28033286,Specific disease- Moderate glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.,Primary Medical Treatment,Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.,Primary Surgical treatment,NE
2016-01-21367,2016,Guedes 2016 Medicine (Baltimore),9600,Primary Medical Treatment VERSUS Primary Surgical treatment IN Specific disease- Advanced glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.,28033286,Specific disease- Advanced glaucoma; Age- 41 to 64 years; Gender- Both; Country- Brazil.,Primary Medical Treatment,Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity.,Primary Surgical treatment,NE
2016-01-19910,2016,Stella 2016 Med Decis Making,71000,Zotarolimus resolute stent VERSUS bare-metal stent IN Specific disease- Coronary artery disease (CAD); Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,26964876,Specific disease- coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,Zotarolimus resolute stent,Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.,bare-metal stent,NE
2016-01-19910,2016,Stella 2016 Med Decis Making,72000,Everolimus stent VERSUS Bare metal stents (BMS) IN Specific disease- Coronary artery disease (CAD); Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,26964876,Specific disease- coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,Everolimus stent,Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.,Bare metal stents (BMS),NE
2016-01-19910,2016,Stella 2016 Med Decis Making,Dominated,Paclitaxel stent VERSUS Zotarolimus resolute stent IN Specific disease- Coronary artery disease (CAD); Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,26964876,Specific disease- coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,Paclitaxel stent,Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.,Zotarolimus resolute stent,NW
2016-01-19910,2016,Stella 2016 Med Decis Making,Dominated,"Sirolimus stent VERSUS Everolimus stent IN Specific disease- Coronary artery disease (CAD); Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Symptomatic, eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).",26964876,"Specific disease- coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Symptomatic, eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).",Sirolimus stent,Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.,Everolimus stent,NW
2016-01-19910,2016,Stella 2016 Med Decis Making,Dominated,Zotarolimus stent VERSUS Zotarolimus resolute stent IN Specific disease- Coronary artery disease (CAD); Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,26964876,Specific disease- coronary artery disease; Age- 41 to 64 years; Gender- Both; Country- Brazil; Other- Eligible for percutaneous coronary intervention procedure (PCI) using either a bare metal stents (BMS) or a drug-eluting stents (DES).,Zotarolimus stent,Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study.,Zotarolimus resolute stent,NW
2015-01-20853,2015,Toscano 2015 Diabetol Metab Syndr,45000,"Brazil Nationwide Diabetes Screening Program (BNDSP) for type 2 diabetes mellitus VERSUS None IN Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Brazil.",26523154,"Healthy; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Brazil.",Brazil Nationwide Diabetes Screening Program (BNDSP) for type 2 diabetes mellitus,Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience.,None,NE
2015-01-17729,2015,Schluckebier 2015 Lung Cancer,18000,Pemetrexed (500mg/m2) plus carboplatin (AUC5) VERSUS Pemetrexed (500mg/m2) alone IN Specific disease- Advanced non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil.,26143106,Specific disease- Advanced non-small cell lung cancer; Age- Adult; Gender- Both; Country- Brazil.,Pemetrexed (500mg/m2) plus carboplatin (AUC5),Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.,Pemetrexed (500mg/m2) alone,NE
2015-01-15909,2015,Janzon 2015 Heart,4300,Ticagrelor VERSUS Clopidrogel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- Sweden.,25227704,Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- Sweden.,Ticagrelor,Health economic analysis of ticagrelor in patients with acute coronary syndromes  intended for non-invasive therapy.,Clopidrogel,NE
2015-01-15909,2015,Janzon 2015 Heart,5300,Ticagrelor VERSUS Clopidrogel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- United Kingdom.,25227704,Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- United Kingdom.,Ticagrelor,Health economic analysis of ticagrelor in patients with acute coronary syndromes  intended for non-invasive therapy.,Clopidrogel,NE
2015-01-15909,2015,Janzon 2015 Heart,6800,Ticagrelor VERSUS Clopidrogel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- Brazil.,25227704,Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- Brazil.,Ticagrelor,Health economic analysis of ticagrelor in patients with acute coronary syndromes  intended for non-invasive therapy.,Clopidrogel,NE
2015-01-15909,2015,Janzon 2015 Heart,6800,Ticagrelor VERSUS Clopidrogel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- Germany.,25227704,Specific disease- Acute coronary syndromes; Age- Adult; Gender- Not Specified; Country- Germany.,Ticagrelor,Health economic analysis of ticagrelor in patients with acute coronary syndromes  intended for non-invasive therapy.,Clopidrogel,NE
2014-01-16325,2014,Araujo 2014 Aesthet Surg J,260,"Reduction mammaplasty VERSUS None IN Specific disease- breast hypertrophy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Brazil.",24973340,"Specific disease- breast hypertrophy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years; Gender- Female; Country- Brazil.",Reduction mammaplasty,Cost-utility of reduction mammaplasty assessed for the Brazilian public health system.,None,NE
2014-01-15821,2014,Park 2014 Rev Bras Ter Intensiva,Cost-Saving,Extracorporeal membrane oxygenation VERSUS None IN Specific disease- Severe respiratory failure; Age- Unknown; Gender- Not Specified; Country- Brazil.,25295819,Specific disease- Severe respiratory failure; Age- Unknown; Gender- Not Specified; Country- Brazil.,Extracorporeal membrane oxygenation,The economic effect of extracorporeal membrane oxygenation to support adults with severe respiratory failure in Brazil: a hypothetical analysis.,None,SE
2014-01-15805,2014,Costa 2014 Expert Rev Cardiovasc Ther,130000,Percutaneous closure VERSUS Standard/Usual Care- Surgical closure IN Specific disease- Hemodynamically significant atrial septal defects; Age- 0 to 18 years; Gender- Both; Country- Brazil.,25284446,Specific disease- Hemodynamically significant atrial septal defects; Age- 0 to 18 years; Gender- Both; Country- Brazil.,Percutaneous closure,Incremental cost-effectiveness of percutaneous versus surgical closure of atrial  septal defects in children under a public health system perspective in Brazil.,Standard/Usual Care- Surgical closure,NE
2014-01-15558,2014,Ribeiro 2014 Arq Bras Cardiol,2000,"Primary prevention, 20% risk of experiencing cardiovascular event with intermediate dose statin VERSUS Primary prevention, 20% risk of experiencing cardiovascular event with low dose statin IN Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.",25409878,"Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.","Primary prevention, 20% risk of experiencing cardiovascular event with intermediate dose statin","Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.","Primary prevention, 20% risk of experiencing cardiovascular event with low dose statin",NE
2014-01-15558,2014,Ribeiro 2014 Arq Bras Cardiol,2000,"Primary prevention, 20% risk of experiencing cardiovascular event with low dose treatment VERSUS None IN Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.",25409878,"Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.","Primary prevention, 20% risk of experiencing cardiovascular event with low dose treatment","Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.",None,NE
2014-01-15558,2014,Ribeiro 2014 Arq Bras Cardiol,31000,"Primary prevention, 20% risk of experiencing cardiovascular event with high dose statin VERSUS Primary prevention, 20% risk of experiencing cardiovascular event with intermediate dose statin IN Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.",25409878,"Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.","Primary prevention, 20% risk of experiencing cardiovascular event with high dose statin","Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.","Primary prevention, 20% risk of experiencing cardiovascular event with intermediate dose statin",NE
2014-01-15558,2014,Ribeiro 2014 Arq Bras Cardiol,3300,"Secondary prevention of Low Dose Statins VERSUS None IN Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.",25409878,"Specific disease- High low density lipoprotein(LDL) cholesterol level; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Brazil; Other- Recently suffered qualifying cardiovascular event.",Secondary prevention of Low Dose Statins,"Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.",None,NE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
